Lupin is currently trading at Rs. 1495.70, up by 11.05 points or 0.74% from its previous closing of Rs. 1484.65 on the BSE.
The scrip opened at Rs. 1488.00 and has touched a high and low of Rs. 1502.00 and Rs. 1487.30 respectively. So far 56,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2110.00 on 15-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1509.20 and Rs. 1482.00 respectively. The current market cap of the company is Rs. 67,357.00 crore.
The promoters holding in the company stood at 46.76%, while Institutions and Non-Institutions held 42.40% and 10.83% respectively.
Lupin Pharmaceutical Inc, the US subsidiary of pharma major Lupin (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic licensing agreement wherein Lupin would develop multiple pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery technology. MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. MonoSol Rx is a global leader in filmbased drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
